Search

Displaying results 421 - 430 of 1613 in total
  1. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well

  2. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene

  3. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.

  4. Drug

    Delavirdine

    go.drugbank.com/drugs/DB00705
    ApprovedInvestigationalWithdrawn

    A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

  5. Drug

    Managlinat dialanetil

    go.drugbank.com/drugs/DB05518
    Investigational

    CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.

  6. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    N-linked glycosylation site. … heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one

  7. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44181] Hemophilia B is the second most common type of hemophilia,[L44181] with a prevalence of approximately one in 40,000. … The therapy involves a one-time infusion of a viral vector carrying a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX controlled by a liver-specific promotor 1.

  8. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].

  9. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.

  10. Drug

    Dihydroergocornine

    go.drugbank.com/drugs/DB11273
    Approved

    Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. … [T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049]